<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-22T16:23:27Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/346971" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/346971</identifier><datestamp>2025-12-20T02:30:37Z</datestamp><setSpec>com_1810_198332</setSpec><setSpec>com_1810_256064</setSpec><setSpec>col_1810_214775</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>A Lab-on-a-chip System for the Standardised Characterisation of Membrane Active Antimicrobials</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">10.17863/CAM.94385</dc:identifier>
   <dc:creator>Al Nahas, Kareem</dc:creator>
   <uketdterms:authoridentifier xsi:type="uketdterms:ORCID">0000000345685894</uketdterms:authoridentifier>
   <uketdterms:advisor>Keyser, Ulrich</uketdterms:advisor>
   <dcterms:abstract>The continuing evolution of bacterial resistance against commercially available antibiotics
is recognised as a global health threat, and the discovery of novel antimicrobials is urgently
required. Antimicrobial peptides (AMPs) are emerging as important players in the fight
against antibiotic resistance. In parallel, the field of microfluidics is maturing, and its
benefits are being exploited in applications related to biomimicry and standardised testing.
Developing a fundamental understanding of the modes of action of AMPs against membrane
models is critical for developing these compounds into novel therapeutics. Throughout
my studies, my efforts have been focused on developing microfluidic platforms that can
streamline the evaluation of membrane active peptides in a systematic and standardised
manner. As a result, I present the "GUV Studio", a bespoke multilayer microfluidic platform
to quantify membranolytic efficacy and characterise the mode of action of AMPs. The
platform is a biomimetic vesicle-based screening assay, which integrates an element for
the high-throughput generation of Giant Unilamellar Vesicles (GUVs) in physiological salt
concentrations on demand. Thousands of GUVs are individually immobilised downstream
in hydrodynamic traps connected to separate perfusion inlets that facilitate the total fluid
exchange of the solutions surrounding the vesicles, and enable the controlled, continuous
administration of peptides for 8 different experiments in parallel. Membranolytic activity is
expressed as a function of the time needed for an encapsulated dye to leak out of individual
GUVs as a result of membrane permeabilisation or lysis. The platform has been used to
study 20 native and de novo synthesised peptides at different concentrations. The results
generated provide novel insights into the activity of a range of membrane active peptides,
and demonstrate the capability of the lab-on-a-chip system to differentiate various modes
of action defined by the response of the vesicle population to the peptides. My platform
provides a quantitative, high-resolution tool to investigate the activity of any membrane-active
compounds in a controlled, highly parallelised and high-throughput manner.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2022-03-31</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>eng</dc:language>
   <uketdterms:sponsor>Cambridge-National Physical Laboratory (U.K.) studentship, the Winton Programme for the Physics of Sustainability, the Trinity-Henry Barlow Scholarship, and the ERC (Designer-Pores 647144)</uketdterms:sponsor>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/346971</dcterms:isReferencedBy>
   <dc:identifier xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/bitstreams/c72ff65d-af4f-4099-aa95-e4f544ad2f39/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">11a323bfe1fb51cc9b8914d22450d9ef</uketdterms:checksum>
   <dc:rights>https://www.rioxx.net/licenses/all-rights-reserved/</dc:rights>
   <dc:subject>Microfluidics</dc:subject>
   <dc:subject>antimicrobial peptides</dc:subject>
   <dc:subject>Membrane</dc:subject>
   <dc:subject>Giant Unilamellar Vesicles</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>